Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
daily_trading_volume_value
market_share59.31%
Current ETH GAS: 0.1-1 gwei
Hot BTC ETF: IBIT
Bitcoin Rainbow Chart : Accumulate
Bitcoin halving: 4th in 2024, 5th in 2028
BTC/USDT$ (0.00%)
banner.title:0(index.bitcoin)
coin_price.total_bitcoin_net_flow_value0
new_userclaim_now
download_appdownload_now
daily_trading_volume_value
market_share59.31%
Current ETH GAS: 0.1-1 gwei
Hot BTC ETF: IBIT
Bitcoin Rainbow Chart : Accumulate
Bitcoin halving: 4th in 2024, 5th in 2028
BTC/USDT$ (0.00%)
banner.title:0(index.bitcoin)
coin_price.total_bitcoin_net_flow_value0
new_userclaim_now
download_appdownload_now
daily_trading_volume_value
market_share59.31%
Current ETH GAS: 0.1-1 gwei
Hot BTC ETF: IBIT
Bitcoin Rainbow Chart : Accumulate
Bitcoin halving: 4th in 2024, 5th in 2028
BTC/USDT$ (0.00%)
banner.title:0(index.bitcoin)
coin_price.total_bitcoin_net_flow_value0
new_userclaim_now
download_appdownload_now
Sensonic Stock (SENS): A Guide to Senseonics Holdings

Sensonic Stock (SENS): A Guide to Senseonics Holdings

Looking for information on Sensonic stock? Learn about Senseonics Holdings, Inc. (SENS), its revolutionary implantable CGM technology, recent financial shifts like the 2025 NASDAQ transition, and i...
2024-08-07 08:22:00
share
Article rating
4.3
103 ratings

When investors search for sensonic stock, they are typically looking for Senseonics Holdings, Inc. (SENS). Headquartered in Germantown, Maryland, Senseonics is a prominent medical technology company focused on transforming the lives of people with diabetes. The company is best known for developing long-term, implantable continuous glucose monitoring (CGM) systems that offer a significant alternative to traditional daily-wear sensors.

Company History and Founding

Senseonics has a long-standing history in medical research, with its roots tracing back to the late 1990s. Over the decades, the company evolved from a research-stage entity into a commercial-stage manufacturer. Its primary mission remains the same: to reduce the burden of diabetes management by providing accurate, long-lasting glucose data through advanced sensor technology.

Core Products and Technology

Eversense CGM Systems

The flagship product under the Senseonics umbrella is the Eversense brand. Unlike competitors whose sensors must be replaced every 10 to 14 days, the Eversense E3 and the newer 365 models are designed to stay under the skin for 90 to 365 days. This long-term usability is a key differentiator for the company in the medical device sector.

Smart Transmitter and Mobile Application

The system consists of three parts: the sensor, a removable smart transmitter, and a mobile app. The transmitter is worn over the sensor and sends real-time glucose readings to the user’s smartphone. It also provides on-body vibratory alerts, ensuring users are notified of high or low glucose levels even without their phones nearby.

Financial Performance and Market Listing

Stock Exchange Listings (NYSE American & NASDAQ)

Historically, Senseonics traded under the ticker SENS on the NYSE American exchange. However, as part of its growth strategy, the company announced a transition to the NASDAQ exchange. As of late 2025, this move aims to increase visibility among institutional investors and improve liquidity for sensonic stock holders.

Key Financial Metrics and Equity Events

Senseonics is generally categorized as a micro-cap or small-cap stock. Key metrics tracked by investors include its revenue growth from sensor sales and its path toward profitability. Significant equity events have shaped the stock’s trajectory, including a 1-for-15 reverse stock split in October 2025, designed to meet exchange listing requirements and attract a broader range of investors.

Strategic Partnerships

Senseonics relies on strategic alliances to expand its market reach. A pivotal partnership is with Ascensia Diabetes Care, which handles the global distribution of Eversense products. Additionally, the company is working on integrations with automated insulin delivery (AID) systems, such as the "twiist" pump, to create a seamless ecosystem for diabetes care.

Regulatory Approvals and Clinical Trials

The company’s growth is heavily tied to regulatory milestones. Senseonics has secured multiple FDA approvals in the United States and CE Marks in Europe. Clinical trial data, such as those from the PROMISE study, have been instrumental in proving the safety and accuracy of their 180-day and 365-day sensors, reinforcing the fundamental value of sensonic stock.

Market Outlook and Analyst Ratings

Wall Street analysts from firms like Mizuho and H.C. Wainwright closely follow Senseonics. The consensus often highlights the company’s unique "first-mover" advantage in long-term implantable tech, though it faces stiff competition from industry giants like Dexcom and Abbott Laboratories. While the medical tech sector can be volatile, Senseonics remains a key player for those interested in healthcare innovation.

Diversifying Your Portfolio

While tracking sensonic stock offers insight into the medical technology sector, many modern investors also look toward the digital asset space to diversify their holdings. If you are interested in exploring the world of cryptocurrencies alongside your traditional stock research, Bitget provides a secure and user-friendly platform to start your journey. From Bitcoin to emerging Web3 tokens, Bitget offers the tools needed to manage a diverse financial portfolio.

To stay updated on market trends and high-growth assets, explore more educational resources on the Bitget Wiki and take control of your financial future today.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.
Buy crypto for $10
Buy now!

Trending assets

Assets with the largest change in unique page views on the Bitget website over the past 24 hours.

Popular cryptocurrencies

A selection of the top 12 cryptocurrencies by market cap.
© 2025 Bitget